CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 194 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,337 | +36.2% | 1,364 | 0.0% | 0.01% | +57.1% |
| Q2 2023 | $14,936 | +25.6% | 1,364 | 0.0% | 0.01% | +16.7% |
| Q1 2023 | $11,894 | +36.4% | 1,364 | -1.9% | 0.01% | +20.0% |
| Q4 2022 | $8,722 | +74.4% | 1,391 | -6.5% | 0.01% | +66.7% |
| Q3 2022 | $5,000 | +25.0% | 1,487 | 0.0% | 0.00% | +50.0% |
| Q2 2022 | $4,000 | +100.0% | 1,487 | +104.5% | 0.00% | +100.0% |
| Q4 2021 | $2,000 | -33.3% | 727 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $3,000 | 0.0% | 727 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $3,000 | 0.0% | 727 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $3,000 | +200.0% | 727 | +127.9% | 0.00% | +100.0% |
| Q4 2020 | $1,000 | 0.0% | 319 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $1,000 | -66.7% | 319 | -42.8% | 0.00% | -50.0% |
| Q3 2019 | $3,000 | -25.0% | 558 | -10.3% | 0.00% | -33.3% |
| Q2 2019 | $4,000 | -50.0% | 622 | 0.0% | 0.00% | -50.0% |
| Q1 2019 | $8,000 | +14.3% | 622 | -2.5% | 0.01% | +100.0% |
| Q3 2018 | $7,000 | – | 638 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |